(VIANEWS) – The Market ended the session with NORDIC NANOVECTOR (NANOV.OL) jumping 27.75% to kr2.44 on Monday while Oslo Børs Benchmark Index_GI rose 0.14% to kr1,195.70.
NORDIC NANOVECTOR’s last close was kr1.91, 42.85% below its 52-week high of kr3.34.
About NORDIC NANOVECTOR
Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting radioimmunotherapy for the treatment of patients with non-hodgkin lymphoma. Its preclinical development products include Humalutin for treatment of non-Hodgkin's lymphoma; Alpha37, a CD37-targeting radioimmunotherapy for treating chronic lymphatic leukemia; and Multiple fully humanized anti-CD37 antibodies for treatment of haematological cancers and autoimmune diseases. The company is also developing 89Zr-NNV003, a CD37-targeting companion PET diagnostic for detection and dosimetry of CD37 expressing tumors. The company has collaboration agreements with Orano Med; Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania development of a CD37-targeting CAR-T in haematological cancers. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NORDIC NANOVECTOR has a trailing twelve months EPS of kr-2.62.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -304.6%.
Yearly Top and Bottom Value
NORDIC NANOVECTOR’s stock is valued at kr2.44 at 22:33 EST, way below its 52-week high of kr3.34 and way above its 52-week low of kr0.65.
More news about NORDIC NANOVECTOR (NANOV.OL).
